Association Between Peripheral Adipokines and Inflammation Markers: A Systematic Review and Meta-Analysis

Graßmann, Sophie; Wirsching, Jan; Eichelmann, Fabian; Aleksandrova, Krasimira

doi:10.1002/oby.21945

Cited by 64 publications

(46 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When linking obesity and inflammatory processes in IBD, adipokines are of particular interest. In several pathological states, the strong correlation between adipokine levels and inflammation severity is demonstrated [57,90,[129][130][131] (Figure 3). However, the results of the discussed studies are contradictory, as there is still no consensus on the exact role they play in the pathogenesis and course of IBD.…”

Section: Adipokinesmentioning

confidence: 91%

Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases

et al. 2019

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are a group of disorders which include ulcerative colitis and Crohn’s disease. Obesity is becoming increasingly more common among patients with inflammatory bowel disease and plays a role in the development and course of the disease. This is especially true in the case of Crohn’s disease. The recent results indicate a special role of visceral adipose tissue and particularly mesenteric adipose tissue, also known as “creeping fat”, in pathomechanism, leading to intestinal inflammation. The involvement of altered adipocyte function and the deregulated production of adipokines, such as leptin and adiponectin, has been suggested in pathogenesis of IBD. In this review, we discuss the epidemiology and pathophysiology of obesity in IBD, the influence of a Western diet on the course of Crohn’s disease and colitis in IBD patients and animal’s models, and the potential role of adipokines in these disorders. Since altered body composition, decrease of skeletal muscle mass, and development of pathologically changed mesenteric white adipose tissue are well-known features of IBD and especially of Crohn’s disease, we discuss the possible crosstalk between adipokines and myokines released from skeletal muscle during exercise with moderate or forced intensity. The emerging role of microbiota and the antioxidative and anti-inflammatory enzymes such as intestinal alkaline phosphatase is also discussed, in order to open new avenues for the therapy against intestinal perturbations associated with IBD.

show abstract

Section: Adipokinesmentioning

confidence: 91%

Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most studied biomarkers include C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-alpha). Data from a meta-analysis investigating potential relationships between the adipose tissue-derived cytokines leptin and adiponectin and inflammatory biomarkers including CRP, IL-6, and TNF-alpha suggested a positive correlation between leptin and all three inflammatory biomarkers, whereas there was a negative correlation with respect to adiponectin and the biomarkers [31]. When adjusted for age, Grassman et al observed that correlations weakened as the age of the participants increased.…”

Section: Gender-specific Differences In Aging Due To Inflammationmentioning

confidence: 99%

Sex Differences in Obesity-Induced Inflammation

Terrazas¹,

Brashear²,

Escoto³

et al. 2020

Translational Studies on Inflammation

View full text Add to dashboard Cite

Obesity is defined as a BMI greater than 25 kg/m 2. Once thought to simply be a nutritional disorder, obesity has become a major health concern characterized by a state of constant low-grade inflammation caused by chronic adiposity. This state of inflammation is characterized by circulating inflammatory mediators, such as IL-6, leptin, and TNF-α, as well as varying levels of glucose-regulating hormones produced by obese adipose tissue. When left untreated, obesity can lead to a number of diseases including, but not limited to, cardiovascular disease, metabolic syndrome, neurodegeneration, type II diabetes mellitus, chronic kidney disease, and infertility. The distribution of adiposity differs in men and women, and these differences, along with the differences in sex hormones and sex hormone levels, can exacerbate or attenuate the course of disease pathology. Obesity can also be exacerbated by stress, which can worsen disease pathogenesis. In this review, we will explore how obesity affects inflammation and disease and how sex can affect the course of these diseases.

show abstract

“…Furthermore, inflammatory biomarkers as high‐sensitivity C‐reactive protein (hs‐CRP) and TNF‐α seem also to be risk factors for both type 2 diabetes and CVDs (Bellou, Belbasis, Tzoulaki, & Evangelou, ; Singh, Morris, Smith, Moxon, & Golledge, ). Their plasma level is usually inversely associated to adiponectin level and directly to the leptin one (Graßmann, Wirsching, Eichelmann, & Aleksandrova, ).…”

Section: Introductionmentioning

confidence: 99%

Three‐arm, placebo‐controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects

Cicero

Fogacci

Bove

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Our double-blind, placebo-controlled, parallel-group, dose-escalation, clinical trial aimed to test the effect of a combined nutraceutical containing bergamot extract (120-mg flavonoids), phytosterols, vitamin C, and chlorogenic acid from dry artichoke extract on 90 overweight dyslipidemic subjects. Participants were randomly allocated to treatment with two pills of either active treatment or placebo, or a combination of both (a pill per treatment). After 8 weeks, all active-treated groups experienced a significant improvement in triglycerides (TG) versus placebo and in low-density lipoprotein cholesterol (LDL-C) versus baseline and placebo treatments. In the high-dosetreated group, also total cholesterol (TC), nonhigh-density lipoprotein cholesterol (non-HDL-C), γ-glutamil transpeptidasi, high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) significantly decreased. At 24-week follow-up, TG levels maintained lower than baseline in all groups. All patients allocated to either low-dose or high-dose active treatment experienced a significant decrease in TG, LDL-C, and homeostatin model assessment of insulin resistance. In subjects taking high-dose active treatment, adiponectin significantly increased, whereas TC, non-HDL-C, insulin (fasting plasma insulin), leptin, leptin/adiponectin ratio, hs-CRP, and TNF-α were significantly reduced. The tested nutraceutical showed to improve lipid and glucose metabolism, adipokines pattern, and systemic inflammation in dyslipidemic overweight subjects.

show abstract

Association Between Peripheral Adipokines and Inflammation Markers: A Systematic Review and Meta-Analysis

Abstract: This is the first quantitative synthesis of human studies on the association between circulating adipokines and inflammation biomarkers. Potential influence of age on these associations requires further evaluation.

Cited by 64 publications

References 40 publications

Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases

Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases

Sex Differences in Obesity-Induced Inflammation

Three‐arm, placebo‐controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects

Contact Info

Product

Resources

About